Spruce Biosciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for Spruce Biosciences (SPRB).

Price Target Range — 10 Quarters

Analyst Consensus — 12 Analysts

2S.Buy

8Buy

2Hold

Consensus RatingBuy# Analysts12Avg. Consensus PT$156Upside to Avg. PT+286.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 24, 2026	Citizens	Jonathan Wolleben	Maintained	Market Outperform	$144
Sep 17, 2026	Lake Street	Daniel Brims	Initiate	Buy	$149
Aug 17, 2026	Guggenheim	Debjit Chattopadhyay	PT Cut	Buy	$123→$104
Aug 13, 2026	Citizens	Jonathan Wolleben	PT Cut	Market Outperform	$150→$144
Jul 13, 2026	B. Riley Securities	Madison El-Saadi	Initiate	Buy	$160
Jun 16, 2026	Guggenheim	Debjit Chattopadhyay	Initiate	Buy	$123
Jun 9, 2026	Jones Trading	Catherine Novack	Initiate	Buy	$135
Jun 1, 2026	HC Wainwright & Co.	Raghuram Selvaraju	PT Cut	Buy	$200→$150
May 14, 2026	Citizens	Jonathan Wolleben	PT Cut	Market Outperform	$170→$150
Apr 27, 2026	Craig-Hallum	Albert Lowe	Initiate	Buy	$140
Mar 10, 2026	Citizens	Jonathan Wolleben	PT Cut	Market Outperform	$180→$170
Mar 10, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$200
Feb 19, 2026	HC Wainwright & Co.	Raghuram Selvaraju	PT Cut	Buy	$220→$200
Dec 23, 2025	Oppenheimer	Leland Gershell	Initiate	Outperform	$283
Dec 22, 2025	HC Wainwright & Co.	Raghuram Selvaraju	Assumes	Buy	$220
Dec 3, 2025	Leerink Partners	Joseph Schwartz	Upgrade	Market Perform→Outperform	$160
Nov 11, 2025	Citizens	Jonathan Wolleben	PT Raise	Market Outperform	$254→$259
Oct 28, 2025	JMP Securities	Jonathan Wolleben	Upgrade	Market Perform→Market Outperform	$254
Oct 21, 2025	Leerink Partners	Joseph Schwartz	PT Raise	Market Perform	$10→$160
Apr 16, 2025	RBC Capital	Gregory Renza	PT Cut	Sector Perform	$2→$1

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Citizens Reiterates Market Outperform on Spruce Biosciences, Maintains $144 Price Target

Citizens analyst Jonathan Wolleben reiterates Spruce Biosciences (NASDAQ:SPRB) with a Market Outperform and maintains $144 price target.

Benzinga Newsdesk

PRO
Lake Street Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $149

Lake Street analyst Daniel Brims initiates coverage on Spruce Biosciences (NASDAQ:SPRB) with a Buy rating and announces Price Target of $149.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Spruce Biosciences, Lowers Price Target to $104

Guggenheim analyst Debjit Chattopadhyay maintains Spruce Biosciences (NASDAQ:SPRB) with a Buy and lowers the price target from $123 to $104.

Benzinga Newsdesk

PRO
Citizens Maintains Market Outperform on Spruce Biosciences, Lowers Price Target to $144

Citizens analyst Jonathan Wolleben maintains Spruce Biosciences (NASDAQ:SPRB) with a Market Outperform and lowers the price target from $150 to $144.

Benzinga Newsdesk

PRO
B. Riley Securities Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $160

B. Riley Securities analyst Madison El-Saadi initiates coverage on Spruce Biosciences (NASDAQ:SPRB) with a Buy rating and announces Price Target of $160.

Benzinga Newsdesk

PRO
Guggenheim Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $123

Guggenheim analyst Debjit Chattopadhyay initiates coverage on Spruce Biosciences (NASDAQ:SPRB) with a Buy rating and announces Price Target of $123.

Benzinga Newsdesk

Spruce Biosciences Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Spruce Biosciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Citizens Reiterates Market Outperform on Spruce Biosciences, Maintains $144 Price Target

PRO
Lake Street Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $149

PRO
Guggenheim Maintains Buy on Spruce Biosciences, Lowers Price Target to $104

PRO
Citizens Maintains Market Outperform on Spruce Biosciences, Lowers Price Target to $144

PRO
B. Riley Securities Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $160

PRO
Guggenheim Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $123

People Also Watch

People Also Watch

Spruce Biosciences Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Spruce Biosciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROCitizens Reiterates Market Outperform on Spruce Biosciences, Maintains $144 Price Target

PROLake Street Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $149

PROGuggenheim Maintains Buy on Spruce Biosciences, Lowers Price Target to $104

PROCitizens Maintains Market Outperform on Spruce Biosciences, Lowers Price Target to $144

PROB. Riley Securities Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $160

PROGuggenheim Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $123

People Also Watch

People Also Watch

PRO
Citizens Reiterates Market Outperform on Spruce Biosciences, Maintains $144 Price Target

PRO
Lake Street Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $149

PRO
Guggenheim Maintains Buy on Spruce Biosciences, Lowers Price Target to $104

PRO
Citizens Maintains Market Outperform on Spruce Biosciences, Lowers Price Target to $144

PRO
B. Riley Securities Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $160

PRO
Guggenheim Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $123